secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2024-03-18T23:59:59+00:00
Accession:  0001493152-24-010303
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma reports Q4 2023 net loss $4.2M; cash $41.3M; clinical programs advance
--------------------------------------------------------------------------------

- Net loss Q4 2023 $4.2M ($0.39/sh) vs $3.4M ($0.31/sh) Q4 2022; full-year loss $1.47/sh.
- Cash, equivalents and marketable securities $41.3M at Dec 31, 2023, down from $55.2M a year earlier.
- LP-184 Phase 1A continuing; initial readout expected late summer/early fall 2024. LP-284 Phase 1 dosed first patients.
- Starlight Therapeutics hired CMO; plans Phase 1B/2 CNS trial in H2 2024. RADR platform surpassed 60B datapoints.
- Share repurchase of 145,348 shares at $3.44/sh in November 2023 reduced outstanding shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315224010303/0001493152-24-010303-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315224010303/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-010303

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer